Piper Sandler Companies (PIPR)
Bid | 337 |
Market Cap | 6.16B |
Revenue (ttm) | 1.58B |
Net Income (ttm) | 210.94M |
EPS (ttm) | 11.86 |
PE Ratio (ttm) | 29.34 |
Forward PE | 20.02 |
Analyst | Hold |
Dividends | $6.3 |
Ask | 371 |
Volume | 76,883 |
Avg. Volume (20D) | 157,889.6 |
Open | 348.49 |
Previous Close | 352.06 |
Day's Range | 345.07 - 352.70 |
52-Week Range | 202.91 - 374.77 |
Beta | 1.44 |
Ex-Dividend Date | Aug 29, 2025 |
About PIPR
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for PIPR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsAnalysts project revenue of ... Unlock content with Pro Subscription

3 weeks ago · https://thefly.com
Dollar Tree price target lowered to $108 from $112 at Piper SandlerPiper Sandler analyst Peter Keith lowered the firm's price target on Dollar Tree to $108 from $112 and keeps a Neutral rating on the shares following Q2 earnings. Q2 was solid with a 6.5% comp that wa...

3 weeks ago · https://thefly.com
Salesforce price target lowered to $315 from $335 at Piper SandlerPiper Sandler lowered the firm's price target on Salesforce to $315 from $335 and keeps an Overweight rating on the shares. Investor sentiment on Salesforce remained bearish going into the July-ending...

1 month ago · https://thefly.com
Ollie's Bargain Outlet price target raised to $150 from $123 at Piper SandlerPiper Sandler raised the firm's price target on Ollie's Bargain Outlet to $150 from $123 and keeps an Overweight rating on the shares. Fundamentals across the discount retailer space have improved as ...

1 month ago · https://thefly.com
Dollar Tree price target raised to $112 from $93 at Piper SandlerPiper Sandler analyst Peter Keith raised the firm's price target on Dollar Tree to $112 from $93 and keeps a Neutral rating on the shares. Fundamentals across the discount retailer space have improved...

1 month ago · https://thefly.com
Piper starts Summit Therapeutics with Neutral on high expectationsPiper Sandler analyst Kelsey Goodwin last night initiated coverage of Summit Therapeutics with a Neutral rating and $21 price target. The firm believes investor expectations for ivonescimab are too hi...